Allogene Therapeutics (ALLO) Receivables - Accured (2018 - 2019)
Allogene Therapeutics (ALLO) posted Receivables - Accured of $2.3 million for Q3 2019, down 28.86% sequentially from $3.3 million in Q2 2019.
Powered by 
Analysis
Allogene Therapeutics (ALLO) Receivables - Accured (2018 - 2019) Analysis & Trends
Allogene Therapeutics has reported Receivables - Accured for 2 years, with the latest figure at $2.3 million in Q3 2019.
- Quarterly Receivables - Accured changed N/A year-over-year to $2.3 million in Q3 2019, while the trailing twelve-month figure through Sep 2019 was $2.3 million (changed N/A YoY) and the FY2018 annual result came in at $3.1 million, changed N/A from the prior year.
- Receivables - Accured retreated to $2.3 million in Q3 2019 per ALLO's latest filing, from $3.3 million in the prior quarter.
- Over five years, Receivables - Accured peaked at $3.4 million in Q1 2019 and troughed at $2.3 million in Q3 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables - Accured (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Allogene Therapeutics | 647.99 Mn | 647.99 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2019 | 2.34 Mn |
| Jun 30, 2019 | 3.29 Mn |
| Mar 31, 2019 | 3.39 Mn |
| Dec 31, 2018 | 3.11 Mn |